Use of an oral composition comprising resveratrol, curcumin, quercetin and NAD precursor in nutritional support

Abstract

The subject of the invention is the use of an oral composition comprising resveratrol, curcumin, quercetin and NAD precursor in nutritional support.

Description

[0001] USE OF AN ORAL COMPOSITION COMPRISING RESVERATROL, CURCUMIN, QUERCETIN AND NAD PRECURSOR IN NUTRITIONAL SUPPORT

[0002] The subject of the invention is the use of an oral composition and belongs to the field of nutrition and medicine in general. The invention will find application in broadly understood nutritional support, and in particular in supporting diet and / or in supporting healthy aging.

[0003] Sirtuin diets and preparations containing sirtuin activators are the subject of intense research. Their action is based on the activation of sirtuins - proteins responsible for, among others, metabolic processes, including those related to glucose and fat metabolism. Sirtuin activation can occur in two ways: through caloric restriction and through the action of natural nutritional ingredients.

[0004] The foundations of the Sirt Diet were originally described in the book "The Sirt Diet: A Breakthrough in Healthy Lifestyle and Weight Loss" by A. Googins and G. Matten. The document discloses a number of Sirt Diet concepts, including division into stages, the use of vegetables and fruits, and the possibility of replacing selected meals with shakes. However, these are rather general and well-known solutions. The publication also does not specify the exact caloric restriction for each stage and does not disclose the exact compositions, especially of ready-made and specially standardized mixtures.

[0005] Despite their advantages, SIRT diets also have their limitations. Firstlt, there is a wide range of foods rich in sirtuin activators. These include grapes rich in resveratrol, citrus fruits rich in naringin, cucumbers, and fisetin- rich blueberries. Selecting the most beneficial substances and their quantities from a large catalog of foods from different climates presents a significant challenge in standardizing SIRT diets and maximizing their effectiveness. Secondly, foods available and inexpensive in certain climates (such as citrus fruits and grapes in the Mediterranean) may be beyond the reach of the daily diet in other latitudes. Furthermore, each sirtuin activator — regardless of its advantages — has its own individual limitations and drawbacks. For example, resveratrol — despite its high potential for sirtuin activation — presents formulation challenges, such as low solubility and bioavailability. Therefore, intensive research and implementation work is currently underway on standardized SIRT dietary supplements and diets containing ingredients that are more optimal in terms of active substances, quantity, and acceptability (including economics). These products and diets must be easily digestible and have favorable storage life (e.g., powders, tablets, and capsules). At the same time, their optimization cannot come at the expense of the solubility, digestibility and bioavailability of the active substances and nutrients they contain.

[0006] An example of a commercially available Sirt diet supplement is the Italian product Yes, Sirt. The supplement is sold in capsule form, containing many ingredients, but in small quantities. These include mate, garcinia, green tea, cocoa, olive (fruit), fenugreek, resveratrol, grape extract, matcha (powder), and nucleotides.

[0007] In addition to weight loss, an emerging health and cultural need is healthy aging. It should be noted that, contrary to popular belief, aging affects everyone. This is because everyone, regardless of age, is exposed to adverse external factors (e.g., UV radiation on the skin) and internal factors (e.g., oxidative stress). Healthy aging, unlike anti - aging, does not involve the currently popular drastic prevention, treatment, or reversal of aging. Instead, healthy aging focuses on accepting this natural phenomenon and supporting health maintenance and optimizing, among other things, appearance, weight, and fitness as we age.

[0008] Furthermore, sirtuins modulate gene expression. It turns out that sirtuin-regulated genes are responsible for, among other things, aging processes (DNA repair, tissue regeneration, signaling between neurons) and metabolic processes (control of metabolism, processes related to glucose metabolism - gluconeogenesis, glycolysis, maintaining optimal glucose and insulin levels).

[0009] The SIRT diet is also rich in antioxidants and promotes the production of antioxidant substances in the body. Therefore, its use in healthy aging would be very beneficial. As with the weight-loss effects of the SIRT diet, selecting the most beneficial antioxidants and their quantities from a large catalog of foods presents a significant challenge in standardizing SIRT diets, maximizing their effectiveness and economic availability. Furthermore, the catalog of foods and antioxidant substances does not necessarily overlap with the catalog of foods and substances that support weight loss, further complicating the selection of a universal composition combining weight-loss and anti-aging benefits.

[0010] On the other hand, recent research indicates that excessive antioxidant use can lead to the unfavorable phenomenon of reductive stress. Therefore, drastic antioxidant intervention can lead to the counterproductive effect of accelerated aging.

[0011] Therefore, the main technical problem solved by the present invention is to provide an alternative - preferably improved - use of selected SIRT diet ingredients within the financial reach of patients. Furthermore, this invention should be easy to take and universal. Preferably, it should combine the potential for weight loss and healthy aging. Another technical problem addressed by the invention is the optimization of use to maximize antioxidant potential while simultaneously reducing the risk of reductive stress. Synergy between ingredients is also expected and potential incompatibilities are avoided.

[0012] The subject of the invention is the use of an oral composition comprising resveratrol, curcumin, quercetin and NAD precursor in nutritional support.

[0013] Preferably, the use according to the invention is characterized in that the nutritional support is a dietary support.

[0014] Preferably, the use according to the invention is characterized in that the nutritional support is a support for healthy aging.

[0015] Preferably, the use according to the invention is characterized in that the NAD precursor is selected from nicotinamide dinucleotide (NAD), reduced nicotinamide dinucleotide (NADH), nicotinic acid (NA), nicotinamide riboside (NR), tryptophan (Trp), nicotinamide (N) and nicotinamide mononucleotide (NMN) and / or a combination thereof.

[0016] Preferably, the use according to the invention is characterized in that the weight ratio of curcumin to resveratrol is 8:2.

[0017] Preferably, the use according to the invention is characterized in that the composition comprises from 10 mg to 200 mg of NAD+ precursor, from 100 mg to 1000 mg of resveratrol, from 10 mg to 200 mg of quercetin and from 10 to 200 mg of curcumin. Preferably, the use according to the invention is characterized in that the composition further comprises at least one substance selected from epigallocatechin gallate (EGCG), piperine, trimethylglycine TMG and leucine or a combination thereof.

[0018] More preferably, the use according to the invention is characterized in that the composition comprises from 10 mg to 200 mg of epigallocatechin gallate (EGCG) and / or from 0.1 mg to 2 mg piperine and / or from 100 mg to 800 mg trimethylglycine (TMG) and / or from 200 mg to 2000 mg leucine or a combination thereof

[0019] Preferably, the use according to the invention is characterized in that the composition is in the form of a powder, granulate, micropellet, microtablet, capsule, tablet, solution, food, dietary supplement and / or food additive.

[0020] Preferably, the use according to the invention is characterized in that the daily energy value of meals is reduced by 15% - 50% TMR.

[0021] More preferably, the use according to the invention is characterized in that the daily energy value of the meals is reduced by 40% TMR.

[0022] Preferably, the use according to the invention is characterized in that the protein constitutes from 20% to 35% of the diet.

[0023] Preferably, the use according to the invention is characterized in that the daily protein intake is at least 1.5 g / kg body weight.

[0024] Preferably, the use according to the invention is characterized in that the diet comprises an addition of 1.5 mg / kg body weight of amino acids per day.

[0025] More preferably, the use according to the invention is characterized in that the amino acids are branched.

[0026] Preferably, the use according to the invention is characterized in that the diet comprises added leucine.

[0027] Preferably, the use according to the invention is characterized in that fat constitutes 30% of the diet.

[0028] Preferably, the use according to the invention is characterized in that carbohydrates constitute from 40% to 50% of the diet.

[0029] More preferably, the use according to the invention is characterized in that simple sugars constitute up to 10% of the diet.

[0030] More preferably, the use according to the invention is characterized in that the daily energy value of the meals is reduced gradually in stages from higher to lower. More preferably, the use according to the invention is characterized in that in stage I the daily energy value of the meals is reduced by 30% - 40% TMR, in stage II the daily energy value of the meals is reduced by 20% - 30% TMR and in stage III the daily energy value of the meals is reduced by 10% - 20% TMR.

[0031] More preferably, the use according to the invention is characterized in that stage I takes 3 days, stage II takes 7 days and stage III takes 14 days.

[0032] One of the innovations is the combination of selected ingredients from the invention and meals. The use according to the invention facilitates the introduction of the Sirtuin diet, accelerates the first results and allows for convenient learning of the principles of preparing Sirtuin meals while on the diet. Depending on preferences and progress, the use of the ingredients according to the invention can be replaced with home-prepared Sirtuin diet meals or ready-made catering.

[0033] The invention provides the first sirtuin diet standardized in terms of ingredients selected to optimize sirtuin effects, in quantities sufficient to adequately support nutritional needs with a standalone sirtuin diet. The form used makes it easier to follow the diet, reducing the risk of discontinuation (as in the case of fasting, for example).

[0034] Resveratrol in the present application is understood as mixture of trans and cisresveratrol, and particularly preferably pure trans-resveratrol.

[0035] NAD precursor is understood as the NAD precursors known in the art and NAD and NADH itself, in particular the nicotinamide dinucleotide (NAD), reduced nicotinamide dinucleotide (NADH), nicotinic acid (NA), nicotinamide riboside (NR), tryptophan (Trp), nicotinamide (N) and nicotinamide mononucleotide (NMN) or combinations thereof.

[0036] Curcuminoids are understood as a group of alkaloids extracted from Turmeric, in particular curcumin, demethoxycurcumin and bisdemethoxycurcumin.

[0037] Healthy aging is understood as activities aimed at optimizing aging-related processes, such as slowing down the metabolic rate and changing body composition in favor of fat tissue through dietary modifications — from energy requirements and protein content to the use of biologically active substances, in proportions that achieve specific physiological effects. Healthy aging focuses on accepting this natural phenomenon and supporting health maintenance and optimizing, among other things, appearance, weight, and fitness as we age.

[0038] TMR is understood as total metabolic rate (TMR), which is the sum of daily energy expenditure related to basal metabolism, necessary to maintain basic life functions (BMR), and physical activity level (PAL). PAL includes activity related to sports and daily chores.

[0039] Example 1

[0040] In one embodiment, resveratrol, curcumin, quercetin and a NAD precursor are used in nutritional support. Such a composition can be prepared by methods known in the art. These methods include mixing the ingredients to obtain a visually homogeneous mixture, or dissolving the mixture of ingredients to obtain a visually homogeneous mixture. In this case, the ingredients are weighed and mixed to obtain a visually homogeneous mixture. One skilled in the art will understand that, without departing from the scope of the invention, the composition according to the invention can be further processed by methods known in the art, e.g., granulated, encapsulated, tableted, micropelletized, added to a food to obtain an even more pharmaceutically and / or nutritionally acceptable form. In a preferred embodiment, the nutritional support is intended to support diet. Such dietary support may be intended to achieve specific dietary goals, e.g., weight loss, appearance change, body shape change, etc. In another preferred embodiment, the nutritional support is intended to support healthy aging. Various NAD precursors and combinations thereof have been investigated. In a preferred embodiment, the NAD precursor is selected from the nicotinamide dinucleotide (NAD), reduced nicotinamide dinucleotide (NADH), nicotinic acid (NA), nicotinamide riboside (NR), tryptophan (Trp), nicotinamide (N) and nicotinamide mononucleotide (NMN) or a combination thereof. Nicotinic acid particularly advantageously combines the functions of an NAD precursor and an ingredient influencing normal energy metabolism.

[0041] The use according to the invention is particularly advantageous because it combines polyphenols acting at the cellular level (requiring direct contact with cells for the antioxidant effect) and polyphenols having an antioxidant effect through action on enzymes (indirect action). For example, NAD promoters (e.g. nicotinamide mononucleotide (NMN) and nicotinic acid (NA)) have a different mechanism of action as sirtuin activators than, for example, resveratrol. This, in turn, increased the effectiveness of the invention and allowed for a reduction in the doses of individual ingredients and the total dose. The use according to the invention requires simultaneous administration of the aforementioned ingredients. In the prior art, for example, there are diets that consider, as part of extensive and multicomponent dietary programs, administration of some of the components discussed herein. However, administering them separately does not achieve the above-mentioned synergy effect and excludes the achievement of the further discussed effect of increasing the absorption of some of the components. Therefore, dividing the ingredients into two separate formulations is excluded, regardless of the time of administration.

[0042] The use according to the invention turned out to comprise an appropriate combination of active ingredients and specific advantageous proportions allowing for increasing the solubility and bioavailability of these ingredients, in particular the typically poorly soluble resveratrol, achieving synergy of selected ingredients and maximizing the antioxidant potential of these ingredients, while reducing the risk of unfavorable reduction potential, reducing the dose of individual active ingredients and the total amount of these substances.

[0043] In particular, substances with strong antioxidant effects include resveratrol, quercetin, and EGCG, which have been selected to minimize the risk of reductive stress (e.g., NAD precursors, particularly NMN and NA). Despite being part of the combination, resveratrol and quercetin are present together with ingredients that reduce the amount of resveratrol and quercetin (e.g., NAD precursors, particularly NMN and NA). Interestingly, resveratrol also has a positive effect on quercetin. Thus, surprisingly, the main active ingredients (resveratrol and the NAD precursor) act on the additional active ingredients (quercetin and EGCG). Meanwhile, the EGCG-enriched composition used comprises these ingredients in their optimal amounts to achieve an antioxidant effect while avoiding the risk of reductive stress.

[0044] Enriching with additional active ingredients further increased the solubility of poorly soluble substances. For example, in one preferred embodiment, the addition of leucine — which, as an active ingredient, increases SIRT 1 expression in liver, brown adipose tissue, and skeletal muscle — increased the solubility (and thus the bioavailability) of resveratrol. In another preferred embodiment, the addition of TMG increased the solubility (and thus the bioavailability) of resveratrol. Resveratrol has a solubility of 35 pg / ml. The use of leucine and / or TMG in the use according to the invention increased the solubility of resveratrol twofold, and in some preferred embodiments (as a complex with leucine) almost threefold. Simultaneously, the use of quercetin increased the bioavailability of resveratrol and curcumin. Regardless of this, a curcumin to resveratrol weight ratio of 8:2 proved particularly beneficial for increasing the bioavailability of resveratrol. Curcumin also acts synergistically with resveratrol, and for this reason, the use according to the invention is standardized for the curcumin content from the curcuminoids (at least 79% of the target amounts indicated in the invention). Therefore, the presence of other curcuminoids is not excluded if a turmeric extract is used instead of pure curcumin. However, such an extract must be standardized for curcumin content to achieve the curcumin content defined in the invention. These benefits are independent of the use of the indicated ingredients due to their beneficial role as sirtuin activators (i.e., as the active substances of the invention).

[0045] Meanwhile, the use of piperine in the composition according to the invention, in addition to its properties as an active substance, increases the bioavailability of sirtuin activators in another way than described above - piperine belongs to the inhibitors of enzymes metabolizing these compounds, thus helping to maintain them in an active, unmetabolized form after absorption.

[0046] Finally, it is worth mentioning that despite its beneficial role as a sirtuin activator and antioxidant, epigallocatechin gallate (EGCG) should preferably be comprised in the composition according to the invention in an amount of no more than 1000 mg due to the possibility of adverse hepatological effects. Due to the high solubility of resveratrol, the synergistic effect of other ingredients and thus high antioxidant potential, the amount of the epigallocatechin gallate (EGCG) content in the composition according to the invention has been limited to approximately 200 mg. This also has the beneficial effect of reducing excessive reduction potential.

[0047] In preferred embodiments, from 100 mg to 1000 mg of resveratrol, from 10 mg to 200 mg of curcumin, from 10 mg to 200 mg of quercetin and from 10 mg to 200 mg of the NAD precursor were used. Table I below presents variants of the tested amounts of the ingredients according to the invention; the ingredients resulted in a homogeneous, wellflowing mixture, regardless of the weight ratios. No negative effects (e.g., gastrointestinal) were observed at higher doses.

[0048] Table I. Tests of various weight ratios of the ingredients used according to the invention.

[0049] In other preferred embodiments, a composition is used which further comprises at least one substance selected from epigallocatechin gallate (EGCG), piperine, trimethylglycine (TMG) and leucine or a combination thereof. In particularly preferred examples, a composition was used that comprised from 10 to 200 mg of epigallocatechin gallate (EGCG) and / or from 0.1 mg to 2 mg piperine and / or from 100 to 800 mg trimethylglycine (TMG) and / or from 200 mg to 2000 mg leucine or a combination thereof. In another preferred embodiment, 500 mg of resveratrol, 100 mg of curcumin, 100 mg of quercetin and 100 mg of epigallocatechin gallate (EGCG) were used. In a particularly preferred embodiment, the above use was supplemented with 10 mg of nicotinic acid. This standardized dose of sirtuin activators was most acceptable in terms of dose size, ease of administration, and organoleptic properties.

[0050] In a preferred embodiment, resveratrol, curcumin, quercetin and an NAD precursor were administered in the form of an oral composition. Many forms of such an oral composition were tested. In preferred embodiments, the composition was prepared in the form of a powder, granulate, micropellet, microtablet, capsule, tablet, solution, food, dietary supplement, and / or food additive. In one particularly preferred embodiment, a composition in the form of micropellets was used. In a second particularly preferred embodiment, a composition in the form of a powder was used. For reasons of convenience of administration, such micropellets and / or powder could be mixed before consumption with a beverage (e.g., juice) or be in a ready-made preparation (e.g., capsules). In a third particularly preferred embodiment, a composition in the form of a food product was used. Such a food product could especially be in the form of a beverage, e.g., a cocktail partially or entirely prepared from the powder or a natural drink with the composition used.

[0051] Example 2

[0052] In a preferred embodiment, the daily energy value of meals is reduced by 15%-50% of the total energy requirement (TMR) for a given body weight (thus introducing controlled caloric restriction). A lower energy intake - at a level of at least 70% of the requirement - increases SIRT3 expression in the liver, muscle, and adipose tissue. Furthermore, energy deficiencies also increase the deacetylation of mitochondrial proteins by SIRT3. On the other hand, excessive energy intake, such as carbohydrates and fats, inhibits the expression and activity of sirtuins. A high-fat diet leads to reduced SIRT1 and SIRT3 expression in the liver and skeletal muscle. It should be noted that the diet according to the invention is not a ketogenic diet, as the underlying mechanisms of action (sirtuin activity) as well as the fat content and quality differ between these diets. In an even more preferred embodiment, the daily energy value of meals is reduced by 40% of the TMR. Reducing the energy value of meals to this level provided the best ratio of beneficial sirtuin activation to the negative effects of caloric restriction.

[0053] In one preferred embodiment, proteins constitute from 20% to 35% of the diet. Weekly, on average 25%. Thus, caloric restriction is accompanied by a higher protein percentage in the diet to protect muscle mass, which is responsible for BMR, metabolic adaptation, and ultimately, indirectly, TMR. In another preferred embodiment, fats constitute 30% of the diet.

[0054] In another preferred embodiment, carbohydrates constitute from 40% to 50%. Weekly, on average 45%. In a more preferred embodiment, simple sugars constitute up to 10% of the diet.

[0055] In one preferred embodiment, daily protein intake reached no less than 1.5g / kg / body weight. This dose, along with caloric restriction not exceeding 40% of TMR, proved optimal for the diet's effects and constitute one of its foundations. Adequate protein intake not only protects muscle mass but is also a crucial aspect for sirtuin activity.

[0056] Adequate protein intake determines:

[0057] • proper muscle protein synthesis (for muscle repair and growth)

[0058] • reduced consumption of muscle proteins as an energy source (catabolism of muscle proteins to glucose for energy production)

[0059] • reduction of undesirable hormonal changes (caloric restrictions may lead to hormonal changes, e.g. lowering IGF-1 or testosterone with increased cortisol levels, intensifying catabolic processes, which will reduce muscle mass)

[0060] • avoiding the body's adaptation to caloric restriction (long fasting may result in the body's adaptation to these conditions, i.e. a reduction in BMR - energy expenditure, which after the end of the diet most often results in an increase in body weight)

[0061] In a preferred embodiment, the daily diet also included 1.5 mg of amino acids per kilogram of body weight. In a more preferred embodiment, the amino acids were branched. Examples of branched amino acids used include leucine, isoleucine and valine. An adequate supply of amino acids, especially branched amino acids, is important in regulating sirtuin activity. Scientific reports indicate higher SIRT1 expression in the heart and diaphragm.

[0062] In a preferred embodiment, the diet comprised leucine. In another preferred embodiment, the composition comprised up to 500 mg of leucine. In another particularly preferred embodiment, the composition contained from 200 mg to 2000 mg of leucine. Leucine administration increases SIRT1 expression in the liver, brown adipose tissue and skeletal muscle. The effect is observed in both low-fat and high-fat diets.

[0063] Example 3

[0064] The diet was tested on a group of 15 women divided into 3 equal groups:

[0065] Group A: with a defined BMI of 22 to 25

[0066] Group B: with a defined BMI > 25 Group C: with a defined BMI > 30

[0067] The inclusion criterion was BMI from the above groups. The exclusion criteria were:

[0068] - BMI <18.5,

[0069] - pregnant and breastfeeding women,

[0070] - surgeries performed in the last 3 months,

[0071] - chemotherapy in the last 6 months,

[0072] - organ failure, including kidney disease

[0073] - eating disorders, i.e. bulimia, anorexia,

[0074] - type I, II diabetes

[0075] - allergies to dietary ingredients

[0076] The invention was used in all groups. The dietary regimen was divided into three stages. In each stage, resveratrol, curcumin, quercetin, and NAD precursor were administered in accordance with the invention or preferred embodiments thereof. These ingredients were administered in the form of shakes prepared, in one preferred embodiment, from micropellets containing the aforementioned ingredients according to the invention, and in the second preferred embodiment, from a powder comprising the aforementioned ingredients according to the invention. The shakes and solid meals were administered in amounts depending on the stage and the associated caloric restrictions.

[0077] In a preferred embodiment, the daily energy value of the meals was reduced gradually in stages from higher to lower. In a particularly preferred embodiment, in stage I the daily energy value of the meals was reduced by 30% - 40% of the TMR, in stage II the daily energy value of the meals was reduced by 20% - 30% of the TMR, and in stage III the daily energy value of the meals was reduced by 10% - 20% of the TMR. In another particularly preferred embodiment, stage I took 3 days, stage II took 7 days, and stage III took 14 days.

[0078] In a preferred embodiment, nutritional support was provided according to the scheme in Table II. Caloric restriction was calculated relative to the current total energy requirement (TMR). The goal of stage I was to facilitate the initiation of the diet, rapid activation of sirtuins using the ingredients according to the invention, caloric deficits for natural sirtuin activation, and a shift in metabolism toward ketosis. The goal of stage II was to maintain sirtuin activity through continued use of the ingredients according to the invention and to exit ketosis (increasing the energy content of the diet, protecting muscle mass). The goal of stage III was to maintain sirtuin activity through the use of the ingredients according to the invention in the form of a ready-made composition and / or meal, protect muscle mass, and exiting a weight-loss diet.

[0079] Table II. Preferred scheme for the use of nutritional support according to the invention.

[0080] In another preferred embodiment, nutritional support was provided according to the scheme in Table III.

[0081] Table III. Nutritional support scheme (*caloric groups were calculated based on TMR for the current body weight. The restriction is calculated from this value)

[0082] Even such short-term (3-week) caloric restriction resulted in a significant increase in SIRT1-4 and SIRT7 mRNA expression compared to an ad libitum diet. The use of the ingredients according to the invention to the nutritional support further enhances and accelerates this effect.

[0083] The effects of the invention were also confirmed by tests of blood glucose and fat levels, which were maintained at normal levels in individuals using the invention. Normal blood glucose and fat levels are also a determinant of achieving (or maintaining) a healthy body composition (fat and fat-free mass). Maintaining such a state also positively influences the aging process.

[0084] The determinations were performed by chromatography on a Hitachi Chromaster HPLC apparatus with a DAD detector and autosampler.

Claims

Claims:

1. Use of an oral composition comprising resveratrol, curcumin, quercetin and NAD precursor in nutritional support.

2. The use according to the preceding claim, characterized in that the nutritional support is a dietary support.

3. The use according to any of the preceding claims, characterized in that the nutritional support is support of healthy aging.

4. The use according to any of the preceding claims, characterized in that the NAD precursor is selected from a nicotinamide dinucleotide (NAD), reduced nicotinamide dinucleotide (NADH), nicotinic acid (NA), nicotinamide riboside (NR), tryptophan (Trp), nicotinamide (N) and nicotinamide mononucleotide (NMN) or a combination thereof.

5. The use according to any of the preceding claims, characterized in that the weight ratio of curcumin to resveratrol is 8:2.

6. The use according to any of the preceding claims, characterized in that the composition comprises from 10 mg to 200 mg of NAD precursor, from 100 mg to 1000 mg of resveratrol, from 10 mg to 200 mg of quercetin and from 10 mg to 200 mg of curcumin.

7. The use according to any of the preceding claims, characterized in that the composition further comprises at least one substance selected from epigallocatechin gallate (EGCG), piperine, trimethylglycine TMG and leucine or a combination thereof.

8. The use according to claim 7, characterized in that the composition comprises from 10 mg to 200 mg of epigallocatechin gallate (EGCG) and / or from 0.1 mg to 2 mg piperine and / or from 100 mg to 800 mg trimethylglycine (TMG) and / or from 200 mg to 2000 mg leucine or a combination thereof.

9. The use according to any of the preceding claims, characterized in that the composition is in the form of a powder, granulate, micropellet, microtablet, capsule, tablet, solution, food, dietary supplement and / or food additive.

10. The use according to any of the preceding claims, characterized in that the daily energy value of the meals is reduced by 15% - 50% TMR.

11. The use according to claim 10, characterized in that the daily energy value of the meals is reduced by 40% TMR.

12. The use according to any of the preceding claims characterized in that the protein constitutes from 20% to 35% of the diet.

13. The use according to any of the preceding claims, characterized in that the daily protein intake is at least 1.5 g / kg body weight.

14. The use according to any of the preceding claims characterized in that the diet comprises an addition of 1.5 mg / kg body weight of amino acids per day.

15. The use according to claim 14, characterized in that the amino acids are branched.

16. Use according to any of the preceding claims, characterized in that the diet comprises added leucine.

17. The use according to any of the preceding claims, characterized in that fat constitutes 30% of the diet.

18. The use according to any of the preceding claims, characterized in that carbohydrates constitute from 40% to 50% of the diet.

19. The use according to claim 18, characterized in that simple sugars constitute up to 10% of the diet.

20. The use according to any of claims 10-19, characterized in that the daily energy value of the meals is reduced gradually in stages from higher to lower.

21. The use according to claim 20, characterized in that in stage I the daily energy value of the meals is reduced by 30% - 40% TMR, in stage II the daily energy value of the meals is reduced by 20% - 30% TMR and in stage III the daily energy value of the meals is reduced by 10% - 20% TMR.

22. The use according to any of claims 20-21 , characterized in that stage I takes 3 days, stage II takes 7 days and stage III takes 14 days.

Images